First Patient With Advanced Breast Cancer Receives First Dose in Clinical Trial of GlycoMimetics' GMI-1359
- Proof-of-concept Phase 1b trial evaluating safety and biomarkers of anti-cancer effect in patients with hormone receptor positive metastatic breast cancer
-
Novel
GlycoMimetics drug candidate targets tumor and bone marrow microenvironment
“The initiation of enrollment is an important milestone in our exploration of GMI-1359 and its potential as a novel approach to treating metastatic cancer,” said GlycoMimetics Senior Vice President of Clinical Development and Chief Medical Officer
More information on this clinical trial can be found at www.clinicaltrials.gov.
About GMI-1359
GMI-1359 is designed to simultaneously inhibit both E-selectin and CXCR4. E-selectin and CXCR4 are both adhesion molecules involved in tumor trafficking and metastatic spread. Preclinical studies indicate that targeting both E-selectin and CXCR4 with a single compound could improve efficacy in the treatment of cancers that involve the bone marrow such as acute myeloid leukemia and multiple myeloma or in solid tumors that metastasize to the bone, such as prostate cancer and breast cancer, as well as in osteosarcoma, a rare pediatric tumor. GMI-1359 has completed a Phase 1 clinical trial in healthy volunteers. The newly initiated Phase 1b clinical study in breast cancer patients is designed to enable investigators to identify an effective dose of the drug candidate and to generate initial biomarker data around the drug’s activity.
About
1
View source version on businesswire.com: https://www.businesswire.com/news/home/20200130005476/en/
Source:
Investor Contact:
Shari Annes
Phone: 650-888-0902
Email: sannes@annesassociates.com
Media Contact:
Jamie Lacey-Moreira
Phone: 410-299-3310
Email: jamielacey@presscommpr.com